2023 Korean Sexually Transmitted Infections Guidelines - Human Papillomavirus Vaccination - Summary of Recommendations

Sep 21, 2026

Upload by Anda

Updated guidance from the Korean Association of Urogenital Tract Infection and Inflammation and the Korea Disease Control and Prevention Agency addresses human papillomavirus (HPV) vaccination against sexually transmitted HPV infections in Korea. The recommendations focus on preventing genital warts and HPV-related cancers including cervical and vulvar cancer, head and neck cancer, anal cancer, and penile cancer. It details which vaccine valencies are used, target age groups, dosing schedules for 2- and 3-dose regimens, guidance for older recipients up to age 45 via clinician consultation, and special dosing for immunocompromised patients, while noting HPV vaccination is not recommended during pregnancy.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages7

Reading Time18 min

AccessFree to download

Summary of Recommendations

Vaccines and Purpose

Recommended Age Groups and Dosing

Special Populations and Contraindications

Special Article Investig Clin Urol 2024;65:108-114. [https://doi.org/10.4111/icu.20230385](https://doi.org/10.4111/icu.20230385)[ ](https://doi.org/10.4111/icu.20230385)[pISSN 2466-0493](pISSN 2466-0493) • eISSN 2466-054X 2023 Korean sexually transmitted infections guidelines by the Korean Association of Urogenital Tract Infection and Inflammation: Human papillomavirus vaccination Chang Il Choi1, Seung-Ju Lee2, Jin Bong Choi3, Tae-Hyoung Kim4, Jeong Woo Lee5, Jun Mo Kim6, Sangrak Bae7 1Department of Urology, Hallym University Dongtan Sacred Heart Hospital, College of Medicine, Hallym University, Hwaseong, 2Department of Urology, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, 3Department of Urology, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, 4Department of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, 5Department of Urology, Kyung Hee University Hospital, Kyung Hee University College of Medicine, Seoul, 6Department of Urology, Soonchunhyang University Buchoen Hospital, Soonchunhyang University College of Medicine, Bucheon, 7Department of Urology, Uijeongbu St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea The Korean Association of Urogenital Tract Infection and Inflammation (KAUTII) and the Korea Disease Control and Prevention Agency updated the guidelines for human papillomavirus (HPV) vaccine against sexually transmitted HPV infections in Korea to respond to changing epidemiologic trends, evolving scientific evidence, and advances in laboratory diagnostics and research. Main purpose and recommendation of vaccination against HPV are as follows: (1) the purpose of HPV vaccine is to reduce the risk of genital warts and HPV-related cancers including cervical and vulvar cancer, head and neck cancer, anal cancer, and penile cancer; (2) in Korea, bivalent (16, 18) vaccines, quadrivalent vaccines (6, 11, 16, 18), and 9-valent vaccines (6, 11, 16, 18, 31, 33, 45, 52, 58) are used depending on the type of HPV; (3) bivalent and quadrivalent vaccines are national immunizations targeting girls aged 11–12 years and low-income young females aged 18–26 years (age and range of inoculation: routinely administered at 11 or 12 years of age, 2 doses at 0 and 6 months for 12–14 years of age; for females aged 15–26 years, 3 doses depending on the type of vaccine; vaccination can be given to those aged up to 45 years through consultation with a clinician); (4) in the case of administering 2 doses, at least 5 months apart; in the case of administering 3 doses, it is recommended to keep 4 weeks between the 1st and 2nd doses, 12 weeks between the 2nd and 3rd doses, and 5 months between the 1st and 3rd doses; (5) immunocompromised patients such as those with HIV, malignant neoplasms, and autoimmune diseases, and those undergoing transplantation or immunosuppressive therapy should receive 3 doses. HPV vaccine is not recommended during pregnancy. Keywords: Guideline; Human papillomavirus; Vaccination This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ([http://creativecommons.org/licenses/by-nc/4.0](http://creativecommons.org/licenses/by-nc/4.0)) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Received: 17 November, 2023 • Accepted: 22 January, 2024 • Published online: 27 February, 2024 Corresponding Author: Sangrak Bae [https://orcid.org/0000-0002-8364-704X](https://orcid.org/0000-0002-8364-704X) Department of Urology, Uijeongbu St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 271 Cheonbo-ro, Uijeongbu 11765, Korea TEL: +82-31-820-5354, FAX: +82-31-847-6133, E-mail: [robinbae97@catholic.ac.kr](robinbae97@catholic.ac.kr) ⓒThe Korean Urological Association [www.icurology.org](www.icuro

FAQs

What is the main purpose of HPV vaccination in the guideline?

The guideline states that HPV vaccination is intended to reduce the risk of genital warts and HPV-related cancers, including cervical and vulvar cancer, head and neck cancer, anal cancer, and penile cancer.

Which HPV vaccine types are used in Korea, and how are they selected?

In Korea, bivalent (16, 18), quadrivalent (6, 11, 16, 18), and 9-valent vaccines (6, 11, 16, 18, 31, 33, 45, 52, 58) are used depending on the HPV type.

What dosing schedules are recommended for 2-dose and 3-dose vaccination?

For 2 doses, the interval should be at least 5 months apart. For 3 doses, the guideline recommends 4 weeks between dose 1 and 2, 12 weeks between dose 2 and 3, and 5 months between dose 1 and 3.

Sep 21, 2026

Upload by Anda